Get the Stockscreener App
4.02
1.23%
-0.05
Ars Pharmaceuticals Inc stock is traded at $4.02, with a volume of 2.33M.
It is down -1.23% in the last 24 hours and down -3.48% over the past month.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
See More
Previous Close:
$4.07
Open:
$4.08
24h Volume:
2.33M
Relative Volume:
1.45
Market Cap:
$399.78M
Revenue:
$98.99M
Net Income/Loss:
$-197.98M
P/E Ratio:
-2.0083
EPS:
-2.0017
Net Cash Flow:
$-175.32M
1W Performance:
-4.96%
1M Performance:
-3.48%
6M Performance:
-50.86%
1Y Performance:
-60.24%
1-Day Range:
$3.8101
$4.08
1-Week Range:
$3.8101
$4.27
52-Week Range:
$3.8101
$13.15
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Name
Ars Pharmaceuticals Inc
Sector
Industry
Phone
858-771-9307
Address
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
4.02 | 399.78M | 98.99M | -197.98M | -175.32M | -2.0017 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Northland Capital | Outperform |
| Nov-04-25 | Resumed | Roth Capital | Buy |
| Sep-04-25 | Initiated | Roth Capital | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-10-25 | Initiated | Oppenheimer | Outperform |
| Aug-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-12-24 | Reiterated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | Raymond James | Outperform |
| Mar-05-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-20-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Initiated | William Blair | Outperform |
| Dec-13-22 | Initiated | SVB Leerink | Outperform |
View All
Ars Pharmaceuticals Inc Stock (SPRY) Latest News
Form 4 ARS Pharmaceuticals Inc For: 12 October By Investing.com - Investing.com Canada
Form 4 ARS Pharmaceuticals Inc For: 12 October By Investing.com - Investing.com South Africa
A stock option with a $4.12 exercise price goes to ARS Pharmaceuticals (SPRY) CEO Donn Casale. - Stock Titan
ARS PHARMACEUTICALS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRY - GlobeNewswire Inc.
ARS PHARMACEUTICALS DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals Investors to Contact the Firm Before October 5th Seeking Lead Plaintiff Role - GlobeNewswire Inc.
Officer Eric Karas proposes selling 100,000 shares of ARS Pharmaceuticals (SPRY). - Stock Titan
Eric Karas proposes selling 100,000 ARS Pharmaceuticals (SPRY) shares after a $69.8K September sale. - Stock Titan
ARS PHARMACEUTICALS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRY - GlobeNewswire Inc.
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Tigo Energy, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmTYGO - GlobeNewswire Inc.
Securities Lawsuit Alert: ARS Pharmaceuticals, Inc. (SPRY)Contact Levi & Korsinsky Before October 5, 2026 - accessnewswire.com
Shareholders of ARS Pharmaceuticals, Inc. (SPRY): Protect Your Rights Before October 5, 2026Contact Levi & Korsinsky - ACCESS Newswire
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire Inc.
מועד אחרון לתביעה ייצוגית נגד DATAVAULT AI: רוזן, יועץ למשקיעים מהימן, קורא למשקיעי Datavault AI Inc. לשכור ייצוג משפטי לקראת מועד חשוב ב- 5 באוקטובר בתביעה ייצוגית בניירות הערך – DVLT - GlobeNewswire Inc.
מועד אחרון לתביעה ייצוגית נגד ARS PHARMACEUTICALS: רוזן, יועץ למשקיעים מהימן, קורא למשקיעי ARS Pharmaceuticals, Inc. לשכור ייצוג משפטי לקראת מועד אחרון חשוב בתביעה הייצוגית בניירות הערך – SPRY - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY - GlobeNewswire Inc.
ARS PHARMACEUTICALS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY - GlobeNewswire Inc.
AARD IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARD - GlobeNewswire Inc.
ARS PHARMACEUTICALS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY - GlobeNewswire Inc.
HDB IMPORTANT DEADLINE: ROSEN, TOP RAKED GLOBAL COUNSEL, Encourages HDFC Bank Limited Investors to Secure Counsel Before Important Deadline in Securities Class ActionHDB - GlobeNewswire Inc.
SPRY Shareholder Alert: ARS Pharmaceuticals Inc. Securities Class Action LawsuitInvestors Should Contact SueWallSt - PR Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - globenewswire.com
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS - GlobeNewswire
SPRY SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Robbins LLP Reminds Investors of the Securities Fraud Class - GlobeNewswire
Richard Lowenthal to sell 35,000 ARS Pharma (SPRY) shares - Stock Titan
ARS Pharmaceuticals (SPRY) officer sold $250K in stock and plans more - Stock Titan
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - Morningstar
Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals - GlobeNewswire
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
ARS Pharma at Cantor Global Healthcare: provider push lifts neffy - Investing.com India
ARS Pharma at Cantor Global Healthcare: provider push lifts neffy By Investing.com - Investing.com Canada
SueWallSt Reminds ARS Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026SPRY - PR Newswire
ARS Pharmaceuticals (SPRY) Short Interest & Short Float | Updated Sep 2026 $SPRY - MarketBeat
רוזן, יועץ למשקיעים מהימן, קורא למשקיעי ARS Pharmaceuticals, Inc. לשכור ייצוג משפטי לקראת מועד אחרון חשוב בתביעה הייצוגית בניירות הערך – SPRY - GlobeNewswire Inc.
SPRY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ARS Pha - The National Law Review
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS - GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY - GlobeNewswire Inc.
SPRY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in ARS Pharmaceuticals Securities LawsuitContact Levi & Korsinsky - PR Newswire
Kaplan Fox Deadline Alert: ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors Have Until October 5, 2026 to Seek a Lead Plaintiff Role - newmediawire.com
Kaplan Fox Deadline Alert: ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors Have Until October 5, 2026 to Seek a Lead Plaintiff Role - Barchart.com
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
ARS Pharmaceuticals (NasdaqGM:SPRY) Stock Forecast & Analyst Predictions - Simply Wall Street
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm - lincolnjournal.com
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY - GlobeNewswire Inc.
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - The Conway Daily Sun
ROSEN, A TOP RANKED LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionSPRY - ACCESS Newswire
Another ARS Pharma (NASDAQ: SPRY) insider stock sale is coming, with the size now disclosed - Stock Titan
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - globenewswire.com
Kaplan Fox Continues to Remind ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors of the Lead Plaintiff Deadline on October 5, 2026 - NewMediaWire
Ars Pharmaceuticals Inc Stock (SPRY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ars Pharmaceuticals Inc Stock (SPRY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ERIC KARAS | Officer |
Sep 30 '26 |
Proposed Sale |
4.32 |
100,000 |
431,560 |
0 |
| RICHARD LOWENTHAL | Officer |
Sep 11 '26 |
Proposed Sale |
5.06 |
35,000 |
176,995 |
0 |
| ERIC KARAS | Officer |
Sep 11 '26 |
Proposed Sale |
4.96 |
14,064 |
69,762 |
0 |
| RICHARD LOWENTHAL | Officer |
Sep 04 '26 |
Proposed Sale |
5.61 |
75,000 |
421,058 |
0 |
| RICHARD LOWENTHAL | Officer |
Sep 03 '26 |
Proposed Sale |
5.84 |
19,805 |
115,564 |
0 |
| RICHARD LOWENTHAL | Officer |
Sep 02 '26 |
Proposed Sale |
5.95 |
840 |
5,000 |
0 |
| SARINA TANIMOTO | Officer |
Sep 01 '26 |
Proposed Sale |
6.01 |
45,388 |
272,850 |
0 |
| SARINA TANIMOTO | Officer |
Aug 31 '26 |
Proposed Sale |
5.82 |
63,289 |
368,099 |
0 |
| RICHARD LOWENTHAL | Officer |
Aug 20 '26 |
Proposed Sale |
5.93 |
25,000 |
148,160 |
0 |
| SARINA TANIMOTO | Officer |
Aug 20 '26 |
Proposed Sale |
5.92 |
25,000 |
147,970 |
0 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):